• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: THERAKOS, INC. THERAKOS CELLEX PHOTOPHERESIS SYSTEM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

THERAKOS, INC. THERAKOS CELLEX PHOTOPHERESIS SYSTEM Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Multiple Organ Failure (3261)
Event Date 10/03/2014
Event Type  Death  
Event Description
Event reported in a literature article: journal of pediatric hematology/oncology 2014;00:000-000.Accepted for publication october 3, 2014."safety and outcomes of extracorporeal photopheresis with the therakos cellex system for graft-versus-host-disease in pediatric patients." (b)(6) year-old boy, one of four patients (all four with liver involvement) in a retrospective review of twelve pediatric patients that failed to respond to the treatment and died of mucormycosis, evolved into mild chronic gvhd (skin).Hsct indication: fa, fanconi anemia donor: (b)(6), matched unrelated donor (b)(6).Stem cell: bm, bone marrow.Onset of gvhd (wk): 8.Gvhd treatment (pre-ecp): csa (cyclosporine), tacr (tacrolimus), mmf (mycophenolate mofetil), mp (methylprednisolone), sirolimus interval between onset of gvhd and ecp (wk): 13.Gvhd type: acute (biopsy proven).Affected organs (stage in agvhd, score in cgvhd): skin (2) degree of gvhd: grade 1 acute gvhd.Improvement: acute: grade 1 to 0.Ecp procedures: 6.Gvhd treatment during ecp: sirolimus.Beginning of improvement (if any) (number of procedures): 4.Survival: expired.Current status: died of mucormycosis, evolved into mild chronic gvhd (skin).The date of death was not reported.
 
Manufacturer Narrative
No lot number was reported; therefore, no batch record review was performed.There were no trends detected for complaint categories, death or multi-organ failure.(b)(6)year old male with grade 1 acute gvhd of fanconi anemia died of mucormycosis; evolved into mild chronic gvhd.Patient only had 6 ecp treatments.This case is serious and not related to ecp therapy.Therakos is reporting this out of abundance of caution.Kit unique identifier (udi)#: (b)(4).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
THERAKOS CELLEX PHOTOPHERESIS SYSTEM
Type of Device
CELLEX
Manufacturer (Section D)
THERAKOS, INC.
bridgewater NJ
Manufacturer (Section G)
HARMAC MEDICAL PRODUCTS
2201 baily ave
buffalo NY 14211
Manufacturer Contact
440 us route 22 east, suite 140
bridgewater, NJ 08807
MDR Report Key4326997
MDR Text Key5253629
Report Number2523595-2014-00323
Device Sequence Number1
Product Code LNR
Combination Product (y/n)N
Reporter Country CodeTU
PMA/PMN Number
P680003
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional,User Facility
Reporter Occupation Physician
Type of Report Initial
Report Date 12/08/2014
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Other Device ID Number10705030100009
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 12/08/2014
Initial Date FDA Received12/11/2014
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Death;
Patient Age12 YR
Patient Weight68
-
-